Home / Homepage Bottom Left / Global dosing hold in fitusiran trials initiated by Sanofi Genzyme to investigate new adverse events

Global dosing hold in fitusiran trials initiated by Sanofi Genzyme to investigate new adverse events

| 09/11/2020

A joint statement of the World Federation of Hemophilia (WFH), European Haemophilia Consortium (EHC) and National Hemophilia Foundation (NHF)

November 6, 2020 – The WFH, EHC and NHF have learned of and subsequently confirmed a decision by Sanofi Genzyme to initiate a voluntary sponsor-led global dosing hold on its full clinical development program for fitusiran due to the identification of new adverse events.

CLICK HERE TO ACCESS FULL STATEMENT

Canadian Hemophilia Society
Privacy Overview

This website uses cookies so that we can provide you with the best user experience possible. Cookie information is stored in your browser and performs functions such as recognising you when you return to our website and helping our team to understand which sections of the website you find most interesting and useful.